A formal Drug Enforcement Administration hearing that began June 29 is now weighing whether marijuana should be moved from Schedule I to Schedule III under the Controlled Substances Act - a process set in motion by a December 2025 executive order from President Donald Trump. The hearing matters to cannabis businesses not because it unlocks federal legalization, but because the regulatory and tax consequences of rescheduling are real and structural. For operators tracking federal policy while managing state-level compliance, the distinction between what rescheduling does and what it doesn't do is worth getting straight.
Here's what rescheduling actually changes: it shifts marijuana's classification from a substance considered to have no accepted medical use and high abuse potential - the same tier as heroin and LSD - to Schedule III, a category that includes products like ketamine and codeine formulations. The DEA describes Schedule III substances as having moderate to low potential for physical and psychological dependence. What it does not do is authorize medical or adult-use cannabis at the federal level, override state law, or dissolve the patchwork of conflicting regulations that operators across different markets already manage. For dispensary operators in states with mature regulatory frameworks - the kind of compliance infrastructure tracked by point-of-sale and seed-to-sale platforms like IndicaOnline in Illinois - rescheduling would not reduce the daily compliance load: state licensing, METRC reporting, compliant packaging, lab testing, and age verification requirements all stay in place regardless of what the DEA decides.
The most concrete near-term benefit for cannabis businesses, if the DEA approves rescheduling, falls under federal tax law. Section 280E of the Internal Revenue Code bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Schedule III sits outside that prohibition. That means a licensed cannabis retailer currently unable to deduct rent, payroll, marketing costs, or POS system expenses could, post-rescheduling, treat those as standard business deductions. For operators running on thin margins - which describes most dispensary businesses - that shift in tax treatment would be significant. It wouldn't change state excise tax obligations or licensing fees, but it could meaningfully alter the effective federal tax burden that has long compressed cannabis retail economics.
Tennessee Shows Exactly How Little Federal Rescheduling Changes at the State Level
The Tennessee situation makes this point cleanly. The DEA hearing opened two days before Tennessee's House Bill 1376 took effect on July 1, banning hemp-derived products with THC concentrations above 0.3% - covering THCA, Delta-9, Delta-8, and Delta-10 variants that had been legally sold in the state. Under that law, possession of newly banned products can result in a Class A misdemeanor, fines, and license penalties. Tennessee has no full medical marijuana program; patients with qualifying conditions can only access products containing less than 0.9% THC. Adult-use cannabis remains entirely illegal. Selling more than a half-ounce or cultivating marijuana is a felony.
Federal rescheduling changes none of that. State law operates independently of the DEA's scheduling framework. Tennessee's legislature passed a stricter hemp-derived product ban while the federal rescheduling process was already underway - and did so without any apparent concern that DEA action would preempt it. That's the practical reality operators selling into restrictive markets need to understand: federal policy movement does not create state-level permission, and state legislatures can tighten rules on their own timeline regardless of what Washington does. Retailers in states like Tennessee who built inventory strategies around hemp-derived cannabinoids now face SKU compliance reviews, product reformulations or removals, and the cost of adjusting labeling and retail floor sets - none of which federal rescheduling resolves.
What Operators Should Actually Be Watching
The research pathway is another dimension worth tracking. Schedule I classification has historically created significant barriers to clinical cannabis research - controlled studies require DEA registration and face restrictions that don't apply to other drug categories. Moving marijuana to Schedule III would lower those barriers, potentially accelerating the kind of clinical evidence base that shapes future medical cannabis regulation. For businesses in the medical cannabis space, that matters over a longer horizon; better-documented clinical evidence tends to support expanded patient access programs at the state level.
For now, though, the operational takeaway is measured. Rescheduling - if and when the DEA approves it - delivers a meaningful federal tax benefit for cannabis businesses currently squeezed by 280E. It opens research pathways. It removes marijuana from a classification that no longer reflects the medical consensus about its properties. What it doesn't do is create a licensed dispensary in Tennessee, authorize a new adult-use market, override a state ban on high-potency hemp derivatives, or reduce the compliance burden that any licensed cannabis retailer manages day to day. The hearing continues. Operators should follow it - but plan as if their state law is the document that actually governs their business, because it is.
